{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T18:19:02Z","timestamp":1789841942566,"version":"4.0.1"},"reference-count":180,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1128\/aac.00749-08","type":"journal-article","created":{"date-parts":[[2008,12,16]],"date-time":"2008-12-16T02:12:18Z","timestamp":1229393538000},"page":"849-862","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":200,"title":["New Drugs against Tuberculosis: Problems, Progress, and Evaluation of Agents in Clinical Development"],"prefix":"10.1128","volume":"53","author":[{"given":"Jossy","family":"van den Boogaard","sequence":"first","affiliation":[{"name":"Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gibson S.","family":"Kibiki","sequence":"additional","affiliation":[{"name":"Kilimanjaro Christian Medical Centre, Moshi, Tanzania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elton R.","family":"Kisanga","sequence":"additional","affiliation":[{"name":"Kilimanjaro Christian Medical Centre, Moshi, Tanzania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin J.","family":"Boeree","sequence":"additional","affiliation":[{"name":"Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob E.","family":"Aarnoutse","sequence":"additional","affiliation":[{"name":"Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-197803020-00002"},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1086\/516116","volume":"25","year":"1997","unstructured":"Alangaden, G. J., and S. A. Lerner. 1997. The clinical use of fluoroquinolones for the treatment of mycobacterial diseases. Clin. Infect. Dis.25:1213-1221.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.4.1022-1025.2002"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1106753"},{"key":"e_1_3_2_6_2","unstructured":"Abstr. Am. Chem. Soc. Meet 2004"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-2952(99)00253-1"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.2174\/092986707781368496"},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1093\/jac\/46.4.571","volume":"46","year":"2000","unstructured":"Bemer-Melchior, P., A. Bryskier, and H. B. Drugeon. 2000. Comparison of the in vitro activities of rifapentine and rifampicin against Mycobacterium tuberculosis complex. J. Antimicrob. Chemother.46:571-576.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)09742-8"},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2165\/00003495-200161010-00002","volume":"61","year":"2001","unstructured":"Berning, S. E. 2001. The role of fluoroquinolones in tuberculosis today. Drugs61:9-18.","journal-title":"Drugs"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.167.4.603"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200201-047OC"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1086\/427292"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0007-0971(81)90046-2"},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2165\/00003495-199447060-00008","volume":"47","year":"1994","unstructured":"Brogden, R. N., and A. Fitton. 1994. Rifabutin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. Drugs47:983-1009.","journal-title":"Drugs"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200140050-00002"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200603-360OC"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.1.340-343.2004"},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1136\/bmj.325.7375.1282","volume":"325","year":"2002","unstructured":"Chan, E. D., and M. D. Iseman. 2002. Current medical treatment for tuberculosis. BMJ325:1282-1286.","journal-title":"BMJ"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl227"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/JB.183.24.7058-7066.2001"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/JB.184.9.2420-2428.2002"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2006.01.002"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/31159"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.6243420"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm200"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.8.2442-2444.2003"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00774-05"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/prot.21376"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01474-06"},{"key":"e_1_3_2_32_2","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0041-3879(87)90053-5","volume":"68","year":"1987","unstructured":"Dickinson, J. M., and D. A. Mitchison. 1987. In vitro activity of new rifamycins against rifampicin-resistant M. tuberculosis and MAIS-complex mycobacteria. Tubercle68:177-182.","journal-title":"Tubercle"},{"key":"e_1_3_2_33_2","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/0041-3879(87)90026-2","volume":"68","year":"1987","unstructured":"Dickinson, J. M., and D. A. Mitchison. 1987. In vitro properties of rifapentine (MDL473) relevant to its use in intermittent chemotherapy of tuberculosis. Tubercle68:113-118.","journal-title":"Tubercle"},{"key":"e_1_3_2_34_2","first-page":"370","volume":"11","year":"2007","unstructured":"Donald, P. R., D. Maher, and S. Qazi. 2007. A research agenda to promote the management of childhood tuberculosis within national tuberculosis programmes. Int. J. Tuberc. Lung Dis.11:370-380.","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00554-08"},{"key":"e_1_3_2_36_2","first-page":"273","volume":"8","year":"2008","unstructured":"Drlica, K., X. Zhao, and B. Kreiswirth. 2008. Minimising moxifloxacin resistance with tuberculosis. Lancet Infect. Dis.8:273-275.","journal-title":"Lancet Infect. Dis."},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.3.483"},{"key":"e_1_3_2_38_2","unstructured":"Questions and answers on the recommendation to restrict the use of oral formulations of moxifloxacin-containing medicines. 2008"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/45.4.437"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccm.2005.02.008"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.2.267-274.2002"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/44.3.393"},{"key":"e_1_3_2_43_2","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1093\/jac\/dki376","volume":"56","year":"2005","unstructured":"Gillespie, S. H., R. D. Gosling, L. Uiso, N. E. Sam, E. G. Kanduma, and T. D. McHugh. 2005. Early bactericidal activity of a moxifloxacin and isoniazid combination in smear-positive pulmonary tuberculosis. J. Antimicrob. Chemother.56:1169-1171.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_44_2","first-page":"265","volume":"2","year":"1998","unstructured":"Gillespie, S. H., and N. Kennedy. 1998. Fluoroquinolones: a new treatment for tuberculosis? Int. J. Tuberc. Lung Dis.2:265-271.","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"e_1_3_2_45_2","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1099\/0022-1317-50-6-565","volume":"50","year":"2001","unstructured":"Gillespie, S. H., I. Morrissey, and D. Everett. 2001. A comparison of the bactericidal activity of quinolone antibiotics in a Mycobacterium fortuitum model. J. Med. Microbiol.50:565-570.","journal-title":"J. Med. Microbiol."},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0307-290"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(03)00671-6"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1086\/379328"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200311133492023"},{"key":"e_1_3_2_50_2","unstructured":"Global Alliance for TB Drug Development. 2000. Executive summary of the scientific blueprint for TB drug development. Global Alliance for TB Drug Development New York NY. http:\/\/tballiance.org ."},{"key":"e_1_3_2_51_2","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S0962-8479(96)90088-X","volume":"77","year":"1996","unstructured":"Gonzales, M. J., J. Shoenfelder, L. Dolfi, and P. Olliaro. 1996. Rifabutin-containing regimens for pulmonary tuberculosis: early assessment of treatment effectiveness. Tuber. Lung Dis.77:100.","journal-title":"Tuber. Lung Dis."},{"key":"e_1_3_2_52_2","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1164\/rccm.200305-682OC","volume":"168","year":"2003","unstructured":"Gosling, R. D., L. O. Uiso, N. E. Sam, E. Bongard, E. G. Kanduma, M. Nyindo, R. W. Morris, and S. H. Gillespie. 2003. The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. Am. J. Respir. Crit. Care Med.168:1342-1345.","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.39.1.107-110.2001"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/141.3.626"},{"key":"e_1_3_2_55_2","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1164\/ajrccm\/137.3.719","volume":"137","year":"1988","unstructured":"Heifets, L. B., P. J. Lindholm-Levy, and M. D. Iseman. 1988. Rifabutine: minimal inhibitory and bactericidal concentrations for Mycobacterium tuberculosis. Am. Rev. Respir. Dis.137:719-721.","journal-title":"Am. Rev. Respir. Dis."},{"key":"e_1_3_2_56_2","unstructured":"Drug-drug interaction studies of SQ109 with first-line anti-TB drugs 2008"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.2.653-657.2003"},{"key":"e_1_3_2_58_2","first-page":"69","volume":"12","year":"2008","unstructured":"Hu, Y., A. R. Coates, and D. A. Mitchison. 2008. Comparison of the sterilising activities of the nitroimidazopyran PA-824 and moxifloxacin against persisting Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis.12:69-73.","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki353"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00181-07"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00898-06"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309093291108"},{"key":"e_1_3_2_63_2","first-page":"87s","volume":"36","year":"2002","unstructured":"Iseman, M. D. 2002. Tuberculosis therapy: past, present and future. Eur. Respir. J. Suppl.36:87s-94s.","journal-title":"Eur. Respir. J. Suppl."},{"key":"e_1_3_2_64_2","doi-asserted-by":"crossref","first-page":"607","DOI":"10.2165\/00003495-199856040-00008","volume":"56","year":"1998","unstructured":"Jarvis, B., and H. M. Lamb. 1998. Rifapentine. Drugs56:607-616.","journal-title":"Drugs"},{"key":"e_1_3_2_65_2","doi-asserted-by":"crossref","first-page":"640","DOI":"10.7326\/0003-4819-137-8-200210150-00007","volume":"137","year":"2002","unstructured":"Jasmer, R. M., J. J. Saukkonen, H. M. Blumberg, C. L. Daley, J. Bernardo, E. Vittinghoff, M. D. King, L. M. Kawamura, and P. C. Hopewell. 2002. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann. Intern. Med.137:640-647.","journal-title":"Ann. Intern. Med."},{"key":"e_1_3_2_66_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.7.2118-2124.2003"},{"key":"e_1_3_2_67_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.8.2066"},{"key":"e_1_3_2_68_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.105.087817"},{"key":"e_1_3_2_69_2","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/sj.bjp.0706650","volume":"147","year":"2006","unstructured":"Jia, L., P. E. Noker, L. Coward, G. S. Gorman, M. Protopopova, and J. E. Tomaszewski. 2006. Interspecies pharmacokinetics and in vitro metabolism of SQ109. Br. J. Pharmacol.147:476-485.","journal-title":"Br. J. Pharmacol."},{"key":"e_1_3_2_70_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0705984"},{"key":"e_1_3_2_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2004.11.036"},{"key":"e_1_3_2_72_2","unstructured":"Kaiser Family Foundation. 2006. Open Forum II on Key Issues in TB Drug Development London United Kingdom. http:\/\/www.kaisernetwork.org\/health_cast\/hcast_index.cfm?display=detail&hc=1998 . Accessed 25 May 2008."},{"key":"e_1_3_2_73_2","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2006.12.7"},{"key":"e_1_3_2_74_2","unstructured":"Towards establishing a high-burden guinea pig model for TB chemotherapy 2008"},{"key":"e_1_3_2_75_2","doi-asserted-by":"publisher","DOI":"10.3109\/03602538109011084"},{"key":"e_1_3_2_76_2","first-page":"437","volume":"3","year":"1999","unstructured":"Keung, A., M. G. Eller, K. A. McKenzie, and S. J. Weir. 1999. Single and multiple dose pharmacokinetics of rifapentine in man. II. Int. J. Tuberc. Lung Dis.3:437-444.","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"e_1_3_2_77_2","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1023\/A:1011960428896","volume":"15","year":"1998","unstructured":"Keung, A. C., M. G. Eller, and S. J. Weir. 1998. Single-dose pharmacokinetics of rifapentine in elderly men. Pharm. Res.15:1286-1291.","journal-title":"Pharm. Res."},{"key":"e_1_3_2_78_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.5.1230"},{"key":"e_1_3_2_79_2","doi-asserted-by":"publisher","DOI":"10.1159\/000238006"},{"key":"e_1_3_2_80_2","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1093\/qjmed\/93.11.733","volume":"93","year":"2000","unstructured":"Kochar, D. K., S. Aseri, B. V. Sharma, R. A. Bumb, R. D. Mehta, and S. K. Purohit. 2000. The role of rifampicin in the management of cutaneous leishmaniasis. QJM93:733-737.","journal-title":"QJM"},{"key":"e_1_3_2_81_2","first-page":"71","volume":"51","year":"1976","unstructured":"Kreis, B., S. Pretet, J. Birenbaum, P. Guibout, J. J. Hazeman, E. Orin, S. Perdrizet, and J. Weil. 1976. Two three-month treatment regimens for pulmonary tuberculosis. Bull. Int. Union Tuberc.51:71-75.","journal-title":"Bull. Int. Union Tuberc."},{"key":"e_1_3_2_82_2","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2006.18.6.617"},{"key":"e_1_3_2_83_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.6.2294-2301.2005"},{"key":"e_1_3_2_84_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00276-07"},{"key":"e_1_3_2_85_2","first-page":"879","volume":"119","year":"1979","unstructured":"Long, M. W., D. E. Snider, Jr., and L. S. Farer. 1979. U.S. Public Health Service Cooperative trial of three rifampin-isoniazid regimens in treatment of pulmonary tuberculosis. Am. Rev. Respir. Dis.119:879-894.","journal-title":"Am. Rev. Respir. Dis."},{"key":"e_1_3_2_86_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.12.3482-3486.2001"},{"key":"e_1_3_2_87_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00566-08"},{"key":"e_1_3_2_88_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg480"},{"key":"e_1_3_2_89_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.10.2600-2603.2000"},{"key":"e_1_3_2_90_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0508392103"},{"key":"e_1_3_2_91_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00488-06"},{"key":"e_1_3_2_92_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030466"},{"key":"e_1_3_2_93_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0966-842X(96)10085-8"},{"key":"e_1_3_2_94_2","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1093\/jac\/dkm393","volume":"60","year":"2007","unstructured":"McIlleron, H., J. Norman, T. P. Kanyok, P. B. Fourie, J. Horton, and P. J. Smith. 2007. Elevated gatifloxacin and reduced rifampicin concentrations in a single-dose interaction study amongst healthy volunteers. J. Antimicrob. Chemother.60:1398-1401.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_95_2","first-page":"277","volume":"76","year":"1995","unstructured":"Mitchison, D. A. 1995. Rifabutin in the treatment of newly diagnosed pulmonary tuberculosis. Tuber. Lung Dis.76:277.","journal-title":"Tuber. Lung Dis."},{"key":"e_1_3_2_96_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2672.1996.tb04835.x"},{"key":"e_1_3_2_97_2","first-page":"796","volume":"4","year":"2000","unstructured":"Mitchison, D. A. 2000. Role of individual drugs in the chemotherapy of tuberculosis. Int. J. Tuberc. Lung Dis.4:796-806.","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"e_1_3_2_98_2","doi-asserted-by":"publisher","DOI":"10.2741\/1293"},{"key":"e_1_3_2_99_2","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nbt0205-187","volume":"23","year":"2005","unstructured":"Mitchison, D. A. 2005. Shortening the treatment of tuberculosis. Nat. Biotechnol.23:187-188.","journal-title":"Nat. Biotechnol."},{"key":"e_1_3_2_100_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.1.85"},{"key":"e_1_3_2_101_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.11.2655"},{"key":"e_1_3_2_102_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.9.2073"},{"key":"e_1_3_2_103_2","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1086\/508278","volume":"43","year":"2006","unstructured":"Munsiff, S. S., C. Kambili, and S. D. Ahuja. 2006. Rifapentine for the treatment of pulmonary tuberculosis. Clin. Infect. Dis.43:1468-1475.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_104_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3156.2004.01274.x"},{"key":"e_1_3_2_105_2","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1164\/ajrccm.158.1.9712001","volume":"158","year":"1998","unstructured":"Narita, M., D. Ashkin, E. S. Hollender, and A. E. Pitchenik. 1998. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am. J. Respir. Crit. Care Med.158:157-161.","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"e_1_3_2_106_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200342090-00003"},{"key":"e_1_3_2_107_2","doi-asserted-by":"publisher","DOI":"10.1086\/521894"},{"key":"e_1_3_2_108_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01326-06"},{"key":"e_1_3_2_109_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-004-1109-5"},{"key":"e_1_3_2_110_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00451-06"},{"key":"e_1_3_2_111_2","unstructured":"Relative contribution of moxifloxacin versus isoniazid to rifapentine-based regimens in the murine model of tuberculosis 2008"},{"key":"e_1_3_2_112_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00074-08"},{"key":"e_1_3_2_113_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200507-1047OC"},{"key":"e_1_3_2_114_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200310-1380OC"},{"key":"e_1_3_2_115_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200407-885OC"},{"key":"e_1_3_2_116_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.163.5.2007122"},{"key":"e_1_3_2_117_2","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.ijantimicag.2007.01.015","volume":"29","year":"2007","unstructured":"Papadopoulou, M. V., W. D. Bloomer, and M. R. McNeil. 2007. NLCQ-1 and NLCQ-2, two new agents with activity against dormant Mycobacterium tuberculosis. Int. J. Antimicrob. Agents29:724-727.","journal-title":"Int. J. Antimicrob. Agents"},{"key":"e_1_3_2_118_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.2.627-631.2005"},{"key":"e_1_3_2_119_2","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1056\/NEJMoa055191","volume":"354","year":"2006","unstructured":"Park-Wyllie, L. Y., D. N. Juurlink, A. Kopp, B. R. Shah, T. A. Stukel, C. Stumpo, L. Dresser, D. E. Low, and M. M. Mamdani. 2006. Outpatient gatifloxacin therapy and dysglycemia in older adults. N. Engl. J. Med.354:1352-1361.","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_2_120_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01036-07"},{"key":"e_1_3_2_121_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(07)70112-3"},{"key":"e_1_3_2_122_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00244-06"},{"key":"e_1_3_2_123_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.3.780-782.2004"},{"key":"e_1_3_2_124_2","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.jpba.2006.03.004","volume":"41","year":"2006","unstructured":"Prasad, B., H. Bhutani, and S. Singh. 2006. Study of the interaction between rifapentine and isoniazid under acid conditions. J. Pharm. Biomed. Anal.41:1438-1441.","journal-title":"J. Pharm. Biomed. Anal."},{"key":"e_1_3_2_125_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.279.2.125"},{"key":"e_1_3_2_126_2","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1183\/09031936.93.05060680","volume":"5","year":"1992","unstructured":"Pretet, S., A. Lebeaut, R. Parrot, C. Truffot, J. Grosset, A. T. Dinh-Xuan, et al. 1992. Combined chemotherapy including rifabutin for rifampicin and isoniazid resistant pulmonary tuberculosis. Eur. Respir. J.5:680-684.","journal-title":"Eur. Respir. J."},{"key":"e_1_3_2_127_2","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2174\/157340607780620626","volume":"3","year":"2007","unstructured":"Protopopova, M., E. Bogatcheva, B. Nikonenko, S. Hundert, L. Einck, and C. A. Nacy. 2007. In search of new cures for tuberculosis. Med. Chem.3:301-316.","journal-title":"Med. Chem."},{"key":"e_1_3_2_128_2","first-page":"732","volume":"26","year":"1998","unstructured":"Reith, K., A. Keung, P. C. Toren, L. Cheng, M. G. Eller, and S. J. Weir. 1998. Disposition and metabolism of 14C-rifapentine in healthy volunteers. Drug Metab. Dispos.26:732-738.","journal-title":"Drug Metab. Dispos."},{"key":"e_1_3_2_129_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(02)00239-X"},{"key":"e_1_3_2_130_2","unstructured":"Is it possible to cure TB in weeks instead of months? 2008"},{"key":"e_1_3_2_131_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200602-280OC"},{"key":"e_1_3_2_132_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200507-1072OC"},{"key":"e_1_3_2_133_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0040344"},{"key":"e_1_3_2_134_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01550-06"},{"key":"e_1_3_2_135_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01204-07"},{"key":"e_1_3_2_136_2","first-page":"128","volume":"12","year":"2008","unstructured":"Rustomjee, R., C. Lienhardt, T. Kanyok, G. R. Davies, J. Levin, T. Mthiyane, C. Reddy, A. W. Sturm, F. A. Sirgel, J. Allen, D. J. Coleman, B. Fourie, and D. A. Mitchison. 2008. A phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int. J. Tuberc. Lung Dis.12:128-138.","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"e_1_3_2_137_2","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1093\/jac\/dkm291","volume":"60","year":"2007","unstructured":"Saliu, O. Y., C. Crismale, S. K. Schwander, and R. S. Wallis. 2007. Bactericidal activity of OPC-67683 against drug-tolerant Mycobacterium tuberculosis. J. Antimicrob. Chemother.60:994-998.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_138_2","doi-asserted-by":"crossref","first-page":"7854","DOI":"10.1021\/jm060957y","volume":"49","year":"2006","unstructured":"Sasaki, H., Y. Haraguchi, M. Itotani, H. Kuroda, H. Hashizume, T. Tomishige, M. Kawasaki, M. Matsumoto, M. Komatsu, and H. Tsubouchi. 2006. Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles. J. Med. Chem.49:7854-7860.","journal-title":"J. Med. Chem."},{"key":"e_1_3_2_139_2","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1164\/rccm.200512-1953OC","volume":"173","year":"2006","unstructured":"Schechter, M., R. Zajdenverg, G. Falco, G. L. Barnes, J. C. Faulhaber, J. S. Coberly, R. D. Moore, and R. E. Chaisson. 2006. Weekly rifapentine\/isoniazid or daily rifampin\/pyrazinamide for latent tuberculosis in household contacts. Am. J. Respir. Crit. Care Med.173:922-926.","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"e_1_3_2_140_2","doi-asserted-by":"publisher","DOI":"10.1086\/314059"},{"key":"e_1_3_2_141_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00414-06"},{"key":"e_1_3_2_142_2","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/j.bmcl.2005.02.037","volume":"15","year":"2005","unstructured":"Shindikar, A. V., and C. L. Viswanathan. 2005. Novel fluoroquinolones: design, synthesis, and in vivo activity in mice against Mycobacterium tuberculosis H37Rv. Bioorg. Med. Chem. Lett.15:1803-1806.","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"e_1_3_2_143_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199528020-00003"},{"key":"e_1_3_2_144_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.9.2061"},{"key":"e_1_3_2_145_2","doi-asserted-by":"publisher","DOI":"10.1086\/518663"},{"key":"e_1_3_2_146_2","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.bmcl.2006.02.065","volume":"16","year":"2006","unstructured":"Sriram, D., A. Aubry, P. Yogeeswari, and L. M. Fisher. 2006. Gatifloxacin derivatives: synthesis, antimycobacterial activities, and inhibition of Mycobacterium tuberculosis DNA gyrase. Bioorg. Med. Chem. Lett.16:2982-2985.","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"e_1_3_2_147_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.8.2060"},{"key":"e_1_3_2_148_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/43.suppl_2.83"},{"key":"e_1_3_2_149_2","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1093\/clinids\/23.Supplement_1.S19","volume":"23","year":"1996","unstructured":"Stein, G. E. 1996. Pharmacokinetics and pharmacodynamics of newer fluoroquinolones. Clin. Infect. Dis.23(Suppl. 1):S19-S24.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_150_2","doi-asserted-by":"publisher","DOI":"10.1038\/35016103"},{"key":"e_1_3_2_151_2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/1471-2334-6-97","volume":"6","year":"2006","unstructured":"Szakacs, T. A., D. Wilson, D. W. Cameron, M. Clark, P. Kocheleff, F. J. Muller, and A. E. McCarthy. 2006. Adherence with isoniazid for prevention of tuberculosis among HIV-infected adults in South Africa. BMC Infect. Dis.6:97.","journal-title":"BMC Infect. Dis."},{"key":"e_1_3_2_152_2","first-page":"411","volume":"1","year":"1997","unstructured":"Tam, C. M., S. L. Chan, C. W. Lam, J. M. Dickinson, and D. A. Mitchison. 1997. Bioavailability of Chinese rifapentine during a clinical trial in Hong Kong. Int. J. Tuberc. Lung Dis.1:411-416.","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"e_1_3_2_153_2","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1164\/ajrccm.157.6.9707037","volume":"157","year":"1998","unstructured":"Tam, C. M., S. L. Chan, C. W. Lam, C. C. Leung, K. M. Kam, J. S. Morris, and D. A. Mitchison. 1998. Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis. Initial report. Am. J. Respir. Crit. Care Med.157:1726-1733.","journal-title":"Initial report. Am. J. Respir. Crit. Care Med."},{"key":"e_1_3_2_154_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.6.1259"},{"key":"e_1_3_2_155_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.12.3001"},{"key":"e_1_3_2_156_2","first-page":"276","volume":"9","year":"2005","unstructured":"Tortajada, C., J. Martinez-Lacasa, F. Sanchez, A. Jimenez-Fuentes, M. L. De Souza, J. F. Garcia, J. A. Martinez, and J. A. Cayla. 2005. Is the combination of pyrazinamide plus rifampicin safe for treating latent tuberculosis infection in persons not infected by the human immunodeficiency virus? Int. J. Tuberc. Lung Dis.9:276-281.","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"e_1_3_2_157_2","first-page":"401","volume":"5","year":"1988","unstructured":"Truffot-Pernot, C., A. M. Giroir, L. Maury, and J. Grosset. 1988. Study of the minimal inhibitory concentration of rifabutine (Ansamycin LM 427) for Mycobacterium tuberculosis, Mycobacterium xenopi and Mycobacterium avium-intracellulare. Rev. Mal. Respir.5:401-406. (In French.)","journal-title":"Rev. Mal. Respir."},{"key":"e_1_3_2_158_2","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S1472-9792(08)70015-5","volume":"88","year":"2008","unstructured":"Tuberculosis. 2008. Ll-3858. Tuberculosis (Edinburgh)88:126.","journal-title":"Tuberculosis (Edinburgh)"},{"key":"e_1_3_2_159_2","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S1472-9792(08)70017-9","volume":"88","year":"2008","unstructured":"Tuberculosis. 2008. OPC-67683. Tuberculosis (Edinburgh)88:132-133.","journal-title":"Tuberculosis (Edinburgh)"},{"key":"e_1_3_2_160_2","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S1472-9792(08)70018-0","volume":"88","year":"2008","unstructured":"Tuberculosis. 2008. PA-824. Tuberculosis (Edinburgh)88:134-136.","journal-title":"Tuberculosis (Edinburgh)"},{"key":"e_1_3_2_161_2","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S1472-9792(08)70026-X","volume":"88","year":"2008","unstructured":"Tuberculosis. 2008. SQ109. Tuberculosis (Edinburgh)88:159-161.","journal-title":"Tuberculosis (Edinburgh)"},{"key":"e_1_3_2_162_2","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/S1472-9792(08)70029-5","volume":"88","year":"2008","unstructured":"Tuberculosis. 2008. TMC-207. Tuberculosis (Edinburgh)88:168-169.","journal-title":"Tuberculosis (Edinburgh)"},{"key":"e_1_3_2_163_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.6.2289-2293.2005"},{"key":"e_1_3_2_164_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm038"},{"key":"e_1_3_2_165_2","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1179\/joc.2003.15.1.66","volume":"15","year":"2003","unstructured":"Valerio, G., P. Bracciale, V. Manisco, M. Quitadamo, G. Legari, and S. Bellanova. 2003. Long-term tolerance and effectiveness of moxifloxacin therapy for tuberculosis: preliminary results. J. Chemother.15:66-70.","journal-title":"J. Chemother."},{"key":"e_1_3_2_166_2","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/S0140-6736(98)11467-8","volume":"353","year":"1999","unstructured":"Vernon, A., W. Burman, D. Benator, A. Khan, L. Bozeman, et al. 1999. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Lancet353:1843-1847.","journal-title":"Lancet"},{"key":"e_1_3_2_167_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200711-1736OC"},{"key":"e_1_3_2_168_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.10.4015-4019.2005"},{"key":"e_1_3_2_169_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003343.pub3"},{"key":"e_1_3_2_170_2","doi-asserted-by":"publisher","DOI":"10.1007\/s101560050025"},{"key":"e_1_3_2_171_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200311-1612OC"},{"key":"e_1_3_2_172_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01621-06"},{"key":"e_1_3_2_173_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.7.1853"},{"key":"e_1_3_2_174_2","unstructured":"An expanded DOTS framework for effective tuberculosis control. 2002"},{"key":"e_1_3_2_175_2","unstructured":"Treatment of tuberculosis. 2003"},{"key":"e_1_3_2_176_2","unstructured":"Guidelines for the programmatic management of drug-resistant tuberculosis. 2006"},{"key":"e_1_3_2_177_2","unstructured":"Global tuberculosis control. 2007"},{"key":"e_1_3_2_178_2","doi-asserted-by":"crossref","unstructured":"Anti-tuberculosis drug resistance in the world. 2008","DOI":"10.1016\/S8756-3452(08)70748-5"},{"key":"e_1_3_2_179_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/46.5.669"},{"key":"e_1_3_2_180_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.6.1875-1879.2002"},{"key":"e_1_3_2_181_2","doi-asserted-by":"publisher","DOI":"10.2741\/1291"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00749-08","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00749-08","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T23:22:28Z","timestamp":1684797748000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00749-08"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3]]},"references-count":180,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["10.1128\/AAC.00749-08"],"URL":"https:\/\/doi.org\/10.1128\/aac.00749-08","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,3]]},"assertion":[{"value":"2009-03-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}